MICHAEL LAYFIELD: Open Payments
NPI 1124157250 · AURORA, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,498 in 67 payments from 18 companies in 2025. Trend: 2023 $1,301 · 2024 $1,964 · 2025 $1,498
Food & beverage: $1,498
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $288 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $244 |
| Janssen Biotech, Inc. | 16 | $230 |
| Madrigal Pharmaceuticals | 5 | $160 |
| Ipsen Biopharmaceuticals, Inc | 5 | $99 |
| ABIOMED | 1 | $90 |
| Gilead Sciences, Inc. | 2 | $49 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $47 |
| CONMED Corporation | 2 | $44 |
| Lilly USA, LLC | 2 | $42 |
Products named: TREMFYA, REZDIFFRA, ENTYVIO, RINVOQ, IQIRVO, VIBERZI, EOHILIA, XIFAXAN.
Industry payments across CO — which companies pay providers there.
